The Assembly Public Safety Committee meeting on July 1, 2025, focused on the growing concerns surrounding the drug Xylazine, particularly its presence in fentanyl products. Assemblymembers discussed the implications of Xylazine, a non-addictive drug often mixed with opioids without users' knowledge.

A veterinarian clarified that Xylazine does not lead to addiction like opioids do. Unlike opioids, which require increasing doses to achieve the same effect, Xylazine can be administered repeatedly without escalating effects. This characteristic raises significant safety concerns, especially given that a single vial of Xylazine could potentially be lethal to many individuals.

The discussion highlighted the urgent need for regulatory measures regarding Xylazine, emphasizing that it should be treated with the same caution as other dangerous substances. The committee acknowledged the serious risks associated with its misuse and the necessity for further action to prevent harm to the community.

In conclusion, the meeting underscored the importance of addressing the dangers posed by Xylazine in the context of the ongoing opioid crisis, with calls for stricter controls and public awareness initiatives.